 A retrospective post-hoc analyses of the Phase 3 data, conducted by Reata, identified prior hospitalization for heart failure and the baseline level of brain natriuretic peptide, a marker of fluid retention, as predictors of heart failure hospitalizations in the BEACON trial.For patients without these baseline characteristics, the risk for heart failure events among bardoxolone methyl- and placebo-treated patients was similar.Bardoxolone methyl is an activator of the KEAP1-Nrf2 pathway in mice.